Literature DB >> 3025996

Sulbactam: biochemical factors involved in its synergy with ampicillin.

R Labia, A Morand, V Lelievre, D Mattioni, A Kazmierczak.   

Abstract

Sulbactam is a time-dependent irreversible inhibitor of various beta-lactamases by reversible formation of a Michaelis-type enzyme-inhibitor complex and progressive evolution of this complex into inactivated protein(s). This process is either irreversible (true inactivation) or quasi-irreversible (stable acyl-enzyme). In this way, sulbactam efficiently protects ampicillin from degradation by beta-lactamases. Sulbactam itself exhibits a moderate antibacterial activity that is related to an affinity for the penicillin-binding proteins of various bacterial strains, which is similar to the affinity of penicillins such as ampicillin. However, sulbactam binding differs according to the bacterial species involved. In strains producing either low levels of beta-lactamase or none at all, a synergistic effect, minor but not negligible, can be observed when sulbactam is associated with a beta-lactam antibiotic with a complementary affinity for the target sites.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025996     DOI: 10.1093/clinids/8.supplement_5.s496

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  10 in total

1.  In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.

Authors:  R J Fass; W W Gregory; R F D'Amato; J M Matsen; D N Wright; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.

Authors:  M D Kitzis; B Ferré; A Coutrot; J F Acar; L Gutmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

Review 3.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

4.  Clinical experience with intramuscular sulbactam/ampicillin in the outpatient treatment of various infections. A multicentre trial.

Authors:  M F Güneren
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Authors:  Krisztina M Papp-Wallace; Baui Senkfor; Julian Gatta; Weirui Chai; Magdalena A Taracila; Veerabahu Shanmugasundaram; Seungil Han; Richard P Zaniewski; Brian M Lacey; Andrew P Tomaras; Marion J Skalweit; Michael E Harris; Louis B Rice; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 7.  Ampicillin/sulbactam: current status in severe bacterial infections.

Authors:  Petros I Rafailidis; Eleni N Ioannidou; Matthew E Falagas
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Clinical and pathological evaluation of sulbactam/ampicillin for treatment of experimental bovine pneumonic pasteurellosis.

Authors:  G A Gifford; A A Potter; L A Babiuk
Journal:  Can Vet J       Date:  1988-02       Impact factor: 1.008

9.  Antimicrobial prophylaxis for major head and neck surgery in cancer patients: sulbactam-ampicillin versus clindamycin-amikacin.

Authors:  M Phan; P Van der Auwera; G Andry; M Aoun; G Chantrain; R Deraemaecker; P Dor; D Daneau; P Ewalenko; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem.

Authors:  Louise M Oleksiuk; M Hong Nguyen; Ellen G Press; Cassaundra L Updike; Jessica A O'Hara; Yohei Doi; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.